| RÁČIL, Zdeněk, Filip RÁZGA, Jana DRÁPALOVÁ, Lucie BUREŠOVÁ, Daniela ŽÁČKOVÁ, Martina PALACKOVÁ, Lukáš SEMERÁD, Ludmila MALÁSKOVÁ, Martin HALUZÍK a Jiří MAYER. Mechanism of impaired glucose metabolism during nilotinib therapy in patients with chronic myelogenous leukemia. Haematologica. Pavia, ITALY: Ferrata Storti Foundation, 2013, roč. 98, č. 10, s. "e124"-"e126", 3 s. ISSN 0390-6078. Dostupné z: https://dx.doi.org/10.3324/haematol.2013.086355. |
Další formáty:
BibTeX
LaTeX
RIS
@article{1119840,
author = {Ráčil, Zdeněk and Rázga, Filip and Drápalová, Jana and Burešová, Lucie and Žáčková, Daniela and Palacková, Martina and Semerád, Lukáš and Malásková, Ludmila and Haluzík, Martin and Mayer, Jiří},
article_location = {Pavia, ITALY},
article_number = {10},
doi = {http://dx.doi.org/10.3324/haematol.2013.086355},
keywords = {Nilotinib; insulin resistance},
language = {eng},
issn = {0390-6078},
journal = {Haematologica},
title = {Mechanism of impaired glucose metabolism during nilotinib therapy in patients with chronic myelogenous leukemia.},
url = {http://www.haematologica.org/content/early/2013/05/03/haematol.2013.086355.abstract?cited-by=yes&legid=haematol;haematol.2013.086355v1},
volume = {98},
year = {2013}
}
TY - JOUR
ID - 1119840
AU - Ráčil, Zdeněk - Rázga, Filip - Drápalová, Jana - Burešová, Lucie - Žáčková, Daniela - Palacková, Martina - Semerád, Lukáš - Malásková, Ludmila - Haluzík, Martin - Mayer, Jiří
PY - 2013
TI - Mechanism of impaired glucose metabolism during nilotinib therapy in patients with chronic myelogenous leukemia.
JF - Haematologica
VL - 98
IS - 10
SP - "e124"-"e126"
EP - "e124"-"e126"
PB - Ferrata Storti Foundation
SN - 03906078
KW - Nilotinib
KW - insulin resistance
UR - http://www.haematologica.org/content/early/2013/05/03/haematol.2013.086355.abstract?cited-by=yes&legid=haematol;haematol.2013.086355v1
L2 - http://www.haematologica.org/content/early/2013/05/03/haematol.2013.086355.abstract?cited-by=yes&legid=haematol;haematol.2013.086355v1
N2 - For the first time we have clarified the mechanism of impaired glucose metabolism in CML patients treated with nilotinib, which occurs via rapidly developed tissue insulin resistance and compensatory hyperinsulinemia. It also at least partially explains the fast development of dyslipidemia and probably also PAO in these CML patients. However, further studies that include a larger patient cohort, as well as in vitro tests to confirm postreceptor insulin resistance, are needed, and these are already ongoing in our study group.
ER -
RÁČIL, Zdeněk, Filip RÁZGA, Jana DRÁPALOVÁ, Lucie BUREŠOVÁ, Daniela ŽÁČKOVÁ, Martina PALACKOVÁ, Lukáš SEMERÁD, Ludmila MALÁSKOVÁ, Martin HALUZÍK a Jiří MAYER. Mechanism of impaired glucose metabolism during nilotinib therapy in patients with chronic myelogenous leukemia. \textit{Haematologica}. Pavia, ITALY: Ferrata Storti Foundation, 2013, roč.~98, č.~10, s.~''e124''-''e126'', 3 s. ISSN~0390-6078. Dostupné z: https://dx.doi.org/10.3324/haematol.2013.086355.
|
